Effects of Annual SZ drug on modulating immune responses and efficacy against COVID-19 infectio

Phase 2

Recruiting

• Conditions: Covid-19.; Covid 19 , Virus Identified; U07.1

• Registration Number: IRCT20201001048894N2
• Lead Sponsor: Bandare-abbas University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 21 November 2022

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

Individuals with COVID-19 disease or control group according to specified grouping
Both genders from 20 to 50 years old
Definite infection with COVID-19 (people whose PCR is positive, HRCT is clear evidence of infection and have common symptoms of moderate disease of Covid-19
Signing an informed consent form

Exclusion Criteria

Age less than 20 years and more than 50 years
Pregnancy
People with cardiac arrhythmia, kidney, liver, metabolic or malignant diseases
Mental or skin diseases (rash, dermatitis, psoriasis)
Immunodeficiency diseases
Acute patient conditions and severe illness, the patient has shortness of breath, blood oxygen drop and the disease is worsening

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Immune system parameters. Timepoint: Before intervention and 7, 14 days after intervention. Method of measurement: Using flow cytometry and enzyme-linked immunosorbent assay (ELISA) tests.